The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Long-acting, injectable cabotegravir is as effective as daily PrEP pills at preventing HIV among cisgender men and transgender women who have sex with men.
With 17 million people now accessing antiretroviral treatment worldwide, HIV drug resistance has the potential to unravel progress towards the Fast-Track target of ending AIDS by 2030.
World Health Organisation releases new guidelines recommending all people living with HIV receive antiretroviral treatment, regardless of CD4 count.